Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

Peer Review reports

Original Submission
13 Sep 2011	Submitted	Original manuscript
27 Jan 2012	Reviewed	Reviewer Report - Rudolf P. Wüthrich
8 Feb 2012	Reviewed	Reviewer Report - Andreas Serra
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
4 Apr 2012	Editorially accepted
4 Apr 2012	Article published	10.1186/1471-2369-13-17

Back to article page